Registration of capital reduction by way of a reduction of the nominal value and information on total share capital and number of voting rights

04.10.24 09:01 Uhr



	Registration of capital reduction by way of a reduction of the nominal value and information on total share capital and number of voting rights 4. October 2024 Company Announcement no. 24
	With reference to company announcement no. 19, on 3 June 2024, the extraordinary general meeting in Pharma Equity Group A/S approved a reduction of the company's share capital by a nominal value of DKK 920,667,494.70 from a nominal value of DKK 1,022,963,883.00 to a nominal value of DKK 102,296,388.30 by allocation to a specific reserve pursuant to section 188(1)(3) of the Danish Companies Act. The capital reduction has today been finally registered with the Danish Business Authority and has been carried out by way of a proportional reduction of the denomination of all the company's shares, meaning that the denomination of the shares is reduced from DKK 1.00 to DKK 0.1. Nasdaq Copenhagen has been informed about the capital reduction which will be effected in Nasdaq Copenhagen's systems soonest possible. Pharma Equity Group A/S' updated articles of associations can be found at the company's website. In accordance with section 32 of the Danish Capital Markets Act, Pharma Equity Group A/S hereby announces that its share capital then amounts to a nominal value of DKK 102,296,388.30, corresponding to 1,022,963,883 shares of nominally DKK 0.1 each and a total of 1,022,963,883 voting rights. For further information, please contact:
	Thomas Kaas Selsø, CEO of Pharma Equity Group A/S, phone: +45 4022 2114 Christian Vinding Thomsen, Chairman of the Board of Directors of Pharma Equity Group A/S, phone: +45 2622 7222
	About Pharma Equity Group A/S Pharma Equity Group, a listed company on the Nasdaq Copenhagen stock exchange, is fully dedicated to advancing the medical projects of its subsidiary, Reponex Pharmaceuticals A/S. With an unwavering focus on healthcare, Pharma Equity Group's primary objective is to bring significant value to Reponex Pharmaceuticals' medical projects. The company is committed to providing extensive support, resources, and expertise to drive the development and success of these projects. As a strategic partner, Pharma Equity Group works closely with Reponex Pharmaceuticals, prioritizing the advancement of innovative medical solutions and breakthrough therapies. Every effort is currently directed towards ensuring the utmost success and impact of Reponex Pharmaceuticals' medical projects, with an unwavering dedication to improving global healthcare outcomes. Only when the full potential of Reponex Pharmaceuticals has been unfolded is the intention to explore opportunities to invest in other companies. This approach ensures a strong commitment to the current medical projects and their development, while – on the longer term – remaining open to new strategic investments for continuous growth.